Roche (RHHBY.PK -1.4%) has received premarket approval from the FDA for a new test to assess...

|About: Roche Holding Ltd ADR (RHHBY)|By:, SA News Editor

Roche (RHHBY.PK -1.4%) has received premarket approval from the FDA for a new test to assess patients for the cytomegalovirus. The fully automated process is the first FDA-approved laboratory test for use in quantifying the virus through DNA in human plasma specimens. Roche expects to begin shipping the new test kit in the U.S. in August.